Korsana Biosciences emerged from stealth on February 18, 2026, with $175 million in funding to develop KRSA-028, a next-generation antibody targeting amyloid beta for Alzheimer's treatment34
KRSA-028 was discovered in partnership with Paragon Therapeutics and utilizes the proprietary THETA platform, which uses transferrin receptor 1 (TfR1) engineering to enable brain penetration14
The antibody is engineered as a subcutaneous injection rather than intravenous infusion to improve treatment convenience and reduce adverse effects like amyloid-related imaging abnormalities (ARIA)1
Korsana plans to initiate clinical trials in early 2027, with initial safety data expected in mid-2027 and proof-of-concept amyloid plaque clearance data by end of 20273
Korsana represents the seventh biotech launch from assets developed by Paragon Therapeutics, which acts as a hub-and-spoke model creating focused spinout companies1
Sources:
1. https://www.biopharmatrend.com/news/new-neurodegenerative-disease-biotech-launches-with-175m-to-test-brain-penetrant-antibody-for-alzheimers-1499/
3. https://www.fiercebiotech.com/biotech/korsana-crosses-crowded-alzheimers-field-175m-and-anti-amyloid-antibody
4. https://www.businesswire.com/news/home/20260218747210/en/Korsana-Biosciences-Emerges-from-Stealth-with-$175-Millon-in-Funding-to-Advance-Potential-Best-in-Class-Therapeutics-for-Neurodegenerative-Diseases